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We evaluated the efﬁcacy of single-dose instillation of pirarubicine hydrochloride (THP) in the
chemoprophylaxis of non-muscle-invasive bladder cancer(NMIBC). In a retrospective study, 135 evaluable
patients were assigned to three groups after transurethral resection of bladder tumors (TURBT). In group
1, patients received no adjuvant therapy after TURBT. In group 2, patients received a single-dose of 30 mg
THP in 30 ml normal saline immediately after TURBT. In group 3, patients received 30 mg THP in 30 ml
normal saline 2 weeks after TURBT , and the instillations were repeated for 4 weeks, then every other week
twice and successively monthly for 6 months. Patients were followed with cystoscopy and urine cytology
every 3 months for the ﬁrst 2 years and every 6 months thereafter. The 3- and 5-year non-recurrence rates
were 66.9%, and 66.0%, respectively, in group 1, 85.6%, and 85.6%, respectively, in group 2, and 93.6%,
and 77.9%, respectively, in group 3. There was a signiﬁcant difference only between group 1 and group2 (P
＝0.048). With respect to the recurrence per month, there was a signiﬁcant difference between the 3 groups
(P＝0.014) for the ﬁrst 2 years. However, there was no signiﬁcant difference thereafter. Limitations of our
study are its retrospective and nonrandomized nature with a limited number of patients.
(Hinyokika Kiyo 63 : 183-187, 2017 DOI : 10.14989/ActaUrolJap_63_5_183)































ン（THP）30 mg を生食 30 ml に溶解し使用した．維
持膀胱内注入は原則的に TURBT 2週間後より施行
し，始めの 4回は毎週，次の 2回は隔週，その後 4回
は 4週ごとに施行した．膀胱注入時間は15分とした．
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No of patients 34 54 47
Median age (range) (years) 70.5 (48-88) 72 (49-90) 69 (42-89) 0.327
Gender
Male 28 (82.4％) 40 (74.1％) 38 (80.9％) 0.58
Female 6 (17.6％) 14 (25.9％) 9 (19.1％)
Urinary cytology
I-II 22 (64.7％) 38 (70.4％) 22 (46.8％) 0.008
III 5 (14.7％) 7 (13.0％) 20 (42.6％)
IV-V 4 (11.8％) 4 (7.4％) 3 (6.4％)
Unknown 3 (8.8％) 5 (9.3％) 2 (4.3％)
Tumor size
＜1 cm 15 (44.1％) 25 (46.3％) 18 (38.3％) 0.71
1-3 cm 19 (55.9％) 29 (53.7％) 29 (61.7％)
Tumor grade (1973 WHO)
G1 19 (55.9％) 41 (75.9％) 32 (68.1％) 0.15
G2 15 (44.1％) 13 (24.1％) 15 (31.9％)
No of patients with recurrence 10 (29.4％) 6 (11.1％) 13 (27.7％)
Median followup period (range) (months) 37.9 (3.2-141.0) 31.9 (4.0-68.4) 77.3 (14.1-196.7) ＜0.001
泌62,08,0◆-◆
Fig. 1. Recurrence-free survival rate after transurethral resection. Kaplan-Meier curves for recurrence-free survival
according to intravesical chemotherapy group.
即時単回膀胱内注入は TURBT 直後に THP 30 mg を
生食 30 ml に溶解し使用した．注入時間は15分とし
た．術後の経過観察は膀胱鏡と尿細胞診を術後 2年ま
では 3カ月ごと， 2∼ 5年は 6カ月ごと， 5年以後は
1年ごとに行った．膀胱内注入法別の群間比較は χ2
検定，one-way ANOVA あるいは Kruskal Wallis 検定











Table 2. Univariate and multivariate analysis of risk factors for recurrence after transurethral resection
Factor
Univariated analysis Multivariated analysis
p-value HR (95％CI) p-value
Age (≧70 vs ＜70) 0.362
Gender (Male vs Female) 0.041 3.111 (1.119-8.648) 0.03
Tumor cytology (I, II, III vs IV, V) 0.418
Tumor size (＜1 cm vs ≧1 cm) 0.063
Tumor grade (WHO) (G1 vs G2) 0.581
Intravesical chemotherapy (TUR alone vs Single immediate instillation) 0.048 0.339 (0.122-0.94) 0.038
Table 3. Recurrence per month rate according to intravesical chemotherapy group
TUR alone TUR＋Single immediate instillation TUR＋Multiple delayed instillations P
No of recurrent pts
＜2 years 8 4 3
≧2 years 2 2 10
Recurrence rate/month
＜2 years 0.0109 0.0016 0.0027 0.014
≧2 years 0.0012 0.0013 0.0025 0.091
を用いた．また非再発率は，起算日を TURBT 施行
日とし Kaplan-Meier 法で算出した．有意差検定は














び22例，Ⅲが 5例， 7例および20例，Ⅳ∼Ⅴが 4例，
4例および 3例，腫瘍径は 1 cm 未満が15例，25例お
よび18例，1 cm 以上 3 cm 未満が19例，29例および19
例，2004 WHO 分類による悪性度は全例低悪性度で，
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単回膀胱内注入療法と抗癌剤維持膀胱内注入療法の比
較の評価は定まっていない．Ali-el-Dein らは，epiru-
bicin 50 mg/50 ml の術後即時単回膀胱内注入群と
TUR 2週後より 8週連続投与後毎月 1回で 1年間の
維持膀胱内注入群（計18回）の比較を行ったが，両群
に有意差は認めないことを報告した3)．また，Liu ら
も epirubicin 80 mg/40 ml の術後即時単回膀胱内注入
群と 6∼ 8連続投与後毎月 1回で 1年間の維持膀胱内
注入群（計16∼18回）の比較を行ったが，両群に有意
差を認めなかった4)．一方，Salvaggi らは epirubicin 50
mg/50 ml の術後即時単回膀胱内注入群と TUR 2週













が短い事にあると思われる．Iborra らは ADM あるい
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